Westgene Biopharma Secures RMB 150M Series A Financing for mRNA Drug Development
Westgene Biopharma, an mRNA drug developer based in Chengdu, reportedly raised RMB 150 million (USD...
Deals
Huihe Healthcare Secures Hundreds of Millions in Series C1 and C2 Financing
Shanghai-based Huihe Healthcare, an interventional medical device maker for heart diseases, reportedly raised “hundreds of...
Chaomu Technology Raises Series A+ Funding for Eye Disease Treatments
China-based eye disease treatment technology company Chaomu Technology (Beijing) Co., Ltd reportedly raised close to...
MaxHealth Biotechnology Completes Series B+ Financing Round
Chengdu-based vaccine developer MaxHealth Biotechnology LLC announced the completion of a Series B+ financing round...
F-Star Therapeutics’ Takeover by Sino Biopharmaceutical Delayed Again
UK-based F-Star Therapeutics Inc., (NASDAQ: FSTX) revealed that there has been yet another delay to...
ST Phi Therapeutics Partners with Azenta Life Sciences to Advance Cell Therapy
Hangzhou-based cell therapy specialist ST Phi Therapeutics struck a partnership with US firm Azenta Life...
Everlife Biomed Raises Pre-Series A+ Funding for Immune Exemption Platform
Beijing-based Everlife Biomed reportedly raised “tens of millions” of renminbi in a pre-Series A+ financing...
United Family Healthcare Partners with HSS for Orthopedic Collaboration
United Family Healthcare (UFH), a private comprehensive medical institution based in Beijing, announced an agreement...
Akeso Biopharma Plans IPO on Shanghai’s STAR Market
China-based antibody developer Akeso Biopharma (HKG: 9926) announced that its board of directors has decided...
Tonghua Dongbao Licenses Biosimilar Victoza to Kexing for Emerging Markets
China-based Tonghua Dongbao Pharmaceuticals (SHA: 600867) announced a licensing agreement with compatriot firm Kexing Pharmaceutical...
China Health Group Signs Framework Agreement with Mingcheng Wanda Pharma
China Health Group Ltd (HKG: 0673) announced the signing of a framework agreement with compatriot...
Lavamed Secures USD 40M in Angel and Series A Financing Rounds
Lavamed, a high-end neurointervention device maker based in Suzhou, has successively closed angel and Series...
Tsingke Biotech Secures RMB 400M Series B Financing for Expansion
Beijing Tsingke Biotech Co., Ltd. a gene synthesis company based in Beijing, reportedly raised RMB...
China Medical System Licenses Opzelura from Incyte for Greater China and Southeast Asia
China Medical System Holdings (CMS; HKG: 0867) announced the establishment of a licensing agreement with...
SAFE Raises RMB 500M in Series D Financing to Expand CRO Services
Serve Accurate Faithful Evaluation (SAFE), a contract research organization (CRO) co-founded by the Chinese Academy...
Yifan Pharma Transfers F-627 Distribution Rights in Germany to Apogepha
China-based Yifan Pharmaceutical Co., Ltd (SHE: 002019) announced the transfer of exclusive distribution rights in...
Eli Lilly Ends License for Innovent’s Tyvyt Outside China
Eli Lilly & Co’s (NYSE: LLY) Q3 2022 SEC filing released last month revealed that...
Novartis Partners with Sinopharm for Commercial Promotion of Gleevec and Exjade in China
Swiss giant Novartis (NYSE: NVS) entered into a promotion agreement with China-based Sinopharm Group Co.,...
Luye Pharma Partners with Nhwa and Fine Hin to Commercialize Toludesvenlafaxine
China-based Luye Pharma Group (HKG: 2186), Jiangsu Nhwa Pharmaceutical Co., Ltd (SHE: 002262), and Beijing...
Pediatrix Therapeutics Licenses Tris Pharma’s ADHD Portfolio for Greater China
China-based Pediatrix Therapeutics announced a licensing agreement with US firm Tris Pharma, Inc., obtaining exclusive...